| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-08-27 |
| タイトル |
|
|
タイトル |
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 著者 |
Bose, Prithviraj
| en |
Bose, Prithviraj
The University of Texas MD Anderson Cancer Center
|
Search repository
Xiao, Zhijian
| en |
Xiao, Zhijian
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
|
Search repository
Hasselbalch, Hans C.
Prchal, Josef T.
Duan, Minghui
Yacoub, Abdulraheem
Rampal, Raajit
Kiladjian, Jean Jacques
Hobbs, Gabriela S.
Tashi, Tsewang
下田, 和哉
WEKO
7997
e-Rad_Researcher
90311844
| en |
Shimoda, Kazuya
University of Miyazaki
|
| ja |
下田, 和哉
宮崎大学
|
| ja-Kana |
シモダ, カズヤ
|
Search repository
Kirito, Keita
Gill, Harinder
| en |
Gill, Harinder
The University of Hong Kong Li Ka Shing Faculty of Medicine
|
Search repository
Hou, Hsin An
Lee, Sung Eun
| en |
Lee, Sung Eun
The Catholic University of Korea Seoul St. Mary's Hospital
|
Search repository
Huang, Jian
Li, Bing
Qin, Albert
Yu, Lennex Hsueh Lin
Mascarenhas, John O.
Mesa, Ruben A.
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Purpose of Review: This report summarizes key insights from the 8th Annual International Symposium on Myeloproliferative Neoplasms (MPN Asia 2025). The symposium brought together global experts to discuss advancements in MPN biology, diagnostics, and therapeutics, with a focus on emerging molecular understanding, novel treatment strategies and real-world data. Recent Findings: Molecular profiling has become essential in MPN risk stratification and therapeutic decision-making. High-risk mutations (e.g., ASXL1, TP53) and inflammatory pathways (e.g., IL-17, NF-κB) were shown to correlate with disease progression and transformation. Interferon-based therapy is increasingly used in younger, low-risk, or treatment-naïve patients, and is also being investigated in myelofibrosis and essential thrombocythemia. Ropeginterferon alfa-2b, a novel interferon-based therapy, demonstrated durable clinical efficacy in polycythemia vera. Its high initial-dose and accelerated titration (HIDAT) regimen led to fast achievement of complete hematologic response, rapid reductions in JAK2V617F allele burden, and high complete molecular response rate. Combination regimens involving ruxolitinib and agents such as pelabresib, selinexor, and interferon showed potential for enhanced efficacy. Population-based studies from Asia contributed regional epidemiological and treatment data, reinforcing the role of real-world evidence. Modern prognostic models such as MIPSS70+ v2.0 and GIPSS were discussed for more precise risk prediction. Preliminary findings also suggest ropeginterferon alfa-2b may be a safe option during pregnancy. Summary: MPN Asia 2025 highlighted the growing role of molecular diagnostics and targeted therapeutics in the management of MPNs. Ropeginterferon alfa-2b has emerged as a therapeutic potential across the MPN spectrum. Its early use and personalized strategies are increasingly recognized. Real-world data and regional insights are shaping a more nuanced, globally informed approach to MPN care. |
|
言語 |
en |
| 書誌情報 |
en : Current Hematologic Malignancy Reports
巻 20,
p. 9,
発行日 2025-07-12
|
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1558822X |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
15588211 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s11899-025-00752-3 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
Fulltext (752 KB)
.png)
